<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7399">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00929071</url>
  </required_header>
  <id_info>
    <org_study_id>IIS DP101L - US - 02</org_study_id>
    <nct_id>NCT00929071</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the Addition of 0.3% Lidocaine With EVOLENCE®</brief_title>
  <acronym>AD-1016</acronym>
  <official_title>Safety and Efficacy of the Addition of 0.3% Lidocaine With EVOLENCE®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weinkle, Susan H., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weinkle, Susan H., M.D.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study doctor will give EVOLENCE® mixed with Lidocaine to people in this study to see if
      it effectively reduces pain while injecting and works to correct nasolabial wrinkles.

      The product being used in this study is EVOLENCE®, which is currently marketed in the United
      States for the cosmetic correction of soft tissue contour deficiencies (including wrinkles),
      and been approved by the U.S. Food and Drug Administration (FDA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to determine if the admixture of lidocaine can effectively be used
      to mediate pain relief during the injection of EVOLENCE® while achieving cosmetic
      correction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Assessment of Immediate Post-injection Pain Severity by Subject</measure>
    <time_frame>immediate post-injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects assessment of immediate post-injection pain severity using a visual analogue scale (VAS) 100 mm in length, ranging from no pain (0) to unbearable pain (100).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Immediate Post-injection Pain Severity by Investigator</measure>
    <time_frame>immediate post injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigators assessment of immediate post-injection pain severity using Thermometer Pain Scale (TPS) with a range of 0-10 where 0=no pain and 10=worst possible pain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Aging</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Pain assessment for Evolence/topical anesthetic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assess injection pain severity for a one time 1.0 mL injection of Evolence with 0.2 ml of topical anesthetic, applied 30 minutes prior to injection, to the left nasolabial fold of each participant .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pain assessment for Evolence/Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assess injection pain severity for a one time 1.0 mL injection of Evolence mixed with 0.18 mL of 2% lidocaine (0.3% final lidocaine-HCl) in the right nasolabial fold of each participant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evolence</intervention_name>
    <description>Injectable collagen</description>
    <arm_group_label>Pain assessment for Evolence/topical anesthetic</arm_group_label>
    <arm_group_label>Pain assessment for Evolence/Lidocaine</arm_group_label>
    <other_name>collagen</other_name>
    <other_name>Dermicol-P35 27G</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>admix anesthetic</description>
    <arm_group_label>Pain assessment for Evolence/Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topical anesthetic</intervention_name>
    <arm_group_label>Pain assessment for Evolence/topical anesthetic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understanding and voluntary signature (including date) of an informed consent
             document

          -  Healthy male or female &gt; 18 years of age

          -  Clinical evidence of bilateral, fully visible aging defects in the nasolabial area
             with grades 2.0, 2.5, or 3.0 on the Modified Fitzpatrick Wrinkle Scale (MFWS section
             6.5)

          -  Willingness to receive EVOLENCE® injections in areas of aging defects (wrinkles)

          -  Willingness and ability to comply with the requirements of this protocol

        Exclusion Criteria:

          -  History of multiple severe allergies (food, drug, or substances) and/or anaphylactic
             shock

          -  Subjects with a history of a bleeding disorder, or receiving chronic anti-platelet
             therapy or other chronic anticoagulant medication

          -  Subject on low-dose aspirin therapy or a non-steroidal anti-inflammatory drug, not
             interrupted at least 10 days prior to injection and/or resumed within 1 week after
             injection

          -  History of allergies and/or sensitivity to porcine, bovine and human collagen,
             lidocaine, local anesthetics products or natural rubber latex

          -  Autoimmune or collagen vascular disease, or connective tissue disease

          -  Active skin disease, inflammation or related condition such as infection, psoriasis
             and herpes zoster near or on the nasolabial folds area at study entry and/or within 6
             months prior to study entry

          -  Previous tissue augmentation - permanent implants or hyaluronic acid within 6 months
             or EVOLENCE® within 12 months in the treatment area

          -  Currently being treated with immunosuppressive drugs, chemotherapy agents or systemic
             steroids or has been treated within the last 3 months prior to study entry

          -  Botulinum-toxin A within 6 weeks in treatment area

          -  Received any investigational products within 30 days prior to the study enrollment

          -  Females of Childbearing Potential

          -  Any clinically significant organic disease or other medical condition that in the
             opinion of the PI, makes the subject a poor candidate for participation in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Weinkle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Practice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Susan Weinkle, Private Practice</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>August 4, 2014</lastchanged_date>
  <firstreceived_date>June 24, 2009</firstreceived_date>
  <firstreceived_results_date>December 16, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wrinkles</keyword>
  <keyword>dermal filler</keyword>
  <keyword>collagen</keyword>
  <keyword>soft tissue augmentation</keyword>
  <keyword>lidocaine</keyword>
  <keyword>aesthetic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Assess a difference in immediate post-injection pain of Evolence/topical anesthetic at the left nasolabial fold vs Evolence/Lidocaine at the right nasolabial fold.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pain Assessment</title>
          <description>Assess injection pain of Evolence/topical anesthetic vs Evolence/Lidocaine mixture upon injection</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="63.2" spread="9.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Immediate Post-injection Pain Severity by Subject</title>
        <description>Subjects assessment of immediate post-injection pain severity using a visual analogue scale (VAS) 100 mm in length, ranging from no pain (0) to unbearable pain (100).</description>
        <time_frame>immediate post-injection</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Pain Assessment for Evolence/Topical Anesthetic</title>
            <description>Assess injection pain of Evolence/topical anesthetic left nasolabial fold
collagen: Injectable collagen
topical anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Pain Assessment for Evolence/Lidocaine</title>
            <description>Assess injection pain of Evolence/Lidocaine right nasolabial fold
collagen: Injectable collagen
Lidocaine: admix anesthetic</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of nasolabial folds analyzed</title>
            <units>nasolabial folds</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Assessment of Immediate Post-injection Pain Severity by Subject</title>
            <description>Subjects assessment of immediate post-injection pain severity using a visual analogue scale (VAS) 100 mm in length, ranging from no pain (0) to unbearable pain (100).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.3" spread="2.0"/>
                  <measurement group_id="O2" value="2.0" spread="1.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Immediate Post-injection Pain Severity by Investigator</title>
        <description>Investigators assessment of immediate post-injection pain severity using Thermometer Pain Scale (TPS) with a range of 0-10 where 0=no pain and 10=worst possible pain</description>
        <time_frame>immediate post injection</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Pain Assessment for Evolence/Topical Anesthetic</title>
            <description>Assess injection pain of Evolence/topical anesthetic
collagen: Injectable collagen
topical anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Pain Assessment for Evolence/Lidocaine</title>
            <description>Assess injection pain of Evolence/Lidocaine
collagen: Injectable collagen
Lidocaine: admix anesthetic</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of nasolabial folds analyzed</title>
            <units>nasolabial folds</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Assessment of Immediate Post-injection Pain Severity by Investigator</title>
            <description>Investigators assessment of immediate post-injection pain severity using Thermometer Pain Scale (TPS) with a range of 0-10 where 0=no pain and 10=worst possible pain</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5.2" spread="2.1"/>
                  <measurement group_id="O2" value="2.0" spread="0.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pain Assessment</title>
          <description>Assess injection pain of Evolence/topical anesthetic vs Evolence/Lidocaine mixture upon injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan H. Weinkle, MD</name_or_title>
      <organization>Susan H. Weinkle, MD</organization>
      <phone>941-794-5432</phone>
      <email>sweinkle@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
